As an investor, you will not only serve an important role in reducing the costs of healthcare for the two most devastating diseases – cardiovascular and cancer – you will catalyze an innovation to improve patient outcomes and enhance quality of life. With pCT, the annual global market for using proton therapy for cancer and heart arrhythmia is over $5B.
We are targeting proton therapy centers with commercially sourced PBT systems. Proton therapy has been on an exponential growth path for over 15 years. As of 2022 there are over 120 proton therapy centers worldwide and 85 under development, with over 360 treatment rooms in operation. By 2028, growth projections call for ~50 rooms per year to be added. The world market is projected to be ~750 total treatment rooms by 2028. Our pCT system can be easily retrofitted into an existing proton center room. Assuming that PCT can sell pCT to 70% of the total rooms, the pCT unit sales potential over the next 10 years will be over 500 treatment rooms.
Without pCT many proton centers are struggling financially – the centers have only one treatment modality – solid tumors. With reimbursement revenue under constant pressure and given the high capital acquisition costs and operating expenses, proton centers need a breakthrough to return to profitability.
PCT anticipates significant margins on sales of pCT units, and also plans to offer a fee-for-service model. With pCT, proton centers will return to profitable operation. This will be true for treating patients with cancer, certainly, and once PBT becomes first-line treatment for ablation of cardiac arrhythmias (VT and A-fib) the situation will improve dramatically. Contact us today to learn more about investment opportunities with Proton Calibration Technologies.